Selecta Biotech SE
Selecta Biotech SE
  • Home
  • About us
  • Technology
    • Oligonucleotide therapy
    • ESiNAR-X®
  • Therapeutics
    • Pipeline
    • Oncology
    • Infectious diseases
    • Renal diseases
  • News
    • Publications
    • Media & Press
    • Awards & Certificates
Contact us
Publication

Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor

  • 12. April 2022
Publication

Differences in surface chemistry of iron oxide nanoparticles result in different routes of internalization

  • 18. April 2021
Publication

Surface coating determines the inflammatory potential of magnetite nanoparticles in murine renal podocytes and mesangial cells

  • 5. July 2020
Publication

Chronic myelogenous leukemia on target

  • 14. June 2018
Publication

Selective Therapeutic Intervention: A Challenge against Off-Target Effects

  • 18. July 2017
Publication

Gene expression patterns as predictive biomarkers in hematology-oncology: Principal hurdles on the road to the clinic

  • 31. January 2017
Publication

Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?

  • 21. October 2016
Publication

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia

  • 29. April 2016

Selecta Biotech SE 2025 © All Rights reserved